HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Ryosuke Tsuchiya Yukito Ichinose Harubumi Kato Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nagai, K. Articles by Kato, H. Search for Related Content PubMed PubMed Citation Articles by Nagai, K. Articles by Kato, H. Related Collections Lung - cancer

J Thorac Cardiovasc Surg 2003;125:254-260
© 2003 The American Association for Thoracic Surgery

General Thoracic Surgery (GTS)

A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209)

From the National Cancer Center Hospital East, Chiba,^a the National Cancer Center Hospital, Tokyo,^b the National Kinki Chuo Hospital^c and the Osaka City General Hospital,^d Osaka, the National Kyushu Cancer Center, Fukuoka,^e the Niigata Cancer Center Hospital, Niigata,^f and Tokyo Medical University, Tokyo, Japan.^g

Supported by a Grant-in-Aid for Cancer Research from the Ministry of Health, Labor, and Welfare, Japan.

Received for publication Feb 12, 2002. Revisions requested April 30, 2002; revisions received Aug 28, 2002. Accepted for publication Sept 12, 2002. Address for reprints: Kanji Nagai, MD, Department of Thoracic Oncology, National Cancer Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan (E-mail: knagai{at}east.ncc.go.jp).

Objective: We performed a prospective randomized trial in patients with potentially resectable stage IIIA N2 non-small cell lung cancer to confirm the efficacy of induction chemotherapy before surgical resection.
Methods: Patients with stage IIIA N2 non-small cell lung cancer, all with histologically or cytologically confirmed metastases to the ipsilateral mediastinal lymph nodes, were randomly assigned to receive either three cycles of induction chemotherapy (cisplatin at 80 mg/m² on 1 day and vindesine at 3 mg/m² on 2 days) followed by surgery or surgery alone.
Results: This trial was prematurely terminated because the accrual rate was too slow, which lowered the study's statistical power considerably. From June 1993 through April 1998, a total of 62 patients were enrolled, and 31 patients were assigned to each treatment group. The objective clinical response rate of induction chemotherapy was 28%. Complete resection was achieved in 20 patients in the induction chemotherapy group (65%) and 24 in the surgery alone group (77%). Median follow-up was 6.2 years. Median overall survivals were 17 months for the induction group and 16 months for the surgery alone group. The estimated 1-, 3-, and 5-year survivals, respectively, were 68% (95% confidence interval 51%-85%), 23% (95% confidence interval 8%-38%), and 10% (95% confidence interval 0%-20%) for the induction chemotherapy group and 65% (95% confidence interval 48%-82%), 26% (95% confidence interval 11%-41%), and 22% (95% confidence interval 7%-37%) for the surgery alone group. There was no statistically significant difference in survival between the groups (P = .5274). Treatment-related death was not observed in either group.
Conclusion: This randomized trial to compare induction chemotherapy (cisplatin and vindesine) followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer did not demonstrate a survival difference between the groups, although this may have been because the statistical power was limited.

This article has been cited by other articles:

				S. Mohamed, K. Yasufuku, T. Nakajima, K. Hiroshima, M. Chiyo, S. Yoshida, M. Suzuki, Y. Sekine, K. Shibuya, G. Agamy, et al. Nuclear survivin in pN2 nonsmall cell lung cancer: prognostic and clinical implications Eur. Respir. J., January 1, 2009; 33(1): 127 - 133. [Abstract] [Full Text] [PDF]

				R. Bordoni Consensus Conference: Multimodality Management of Early- and Intermediate-Stage Non-Small Cell Lung Cancer Oncologist, September 1, 2008; 13(9): 945 - 953. [Abstract] [Full Text] [PDF]

				T. Gudbjartsson, E. Gyllstedt, A. Pikwer, and P. Jonsson Early surgical results after pneumonectomy for non-small cell lung cancer are not affected by preoperative radiotherapy and chemotherapy. Ann. Thorac. Surg., August 1, 2008; 86(2): 376 - 382. [Abstract] [Full Text] [PDF]

				W. Zhong, X. Yang, J. Bai, J. Yang, C. Manegold, and Y. Wu Complete mediastinal lymphadenectomy: the core component of the multidisciplinary therapy in resectable non-small cell lung cancer. Eur. J. Cardiothorac. Surg., July 1, 2008; 34(1): 187 - 195. [Abstract] [Full Text] [PDF]

				L. A. Robinson, J. C. Ruckdeschel, H. Wagner Jr, and C. W. Stevens Treatment of Non-small Cell Lung Cancer-Stage IIIA: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 243S - 265S. [Abstract] [Full Text] [PDF]

				Z. Mansour, E. A. Kochetkova, X. Ducrocq, M.-D. Vasilescu, G. Maxant, A. Buggenhout, J.-M. Wihlm, and G. Massard Induction chemotherapy does not increase the operative risk of pneumonectomy! Eur. J. Cardiothorac. Surg., February 1, 2007; 31(2): 181 - 185. [Abstract] [Full Text] [PDF]

				S.-i. Takeda, H. Maeda, T. Okada, T. Yamaguchi, M. Nakagawa, S. Yokota, N. Sawabata, and M. Ohta Results of pulmonary resection following neoadjuvant therapy for locally advanced (IIIA-IIIB) lung cancer. Eur. J. Cardiothorac. Surg., July 1, 2006; 30(1): 184 - 189. [Abstract] [Full Text] [PDF]

				L. W. Martin, A. M. Correa, W. Hofstetter, W. K. Hong, R. Komaki, J. B. Putnam Jr, D. C. Rice, W. R. Smythe, S. G. Swisher, A. A. Vaporciyan, et al. The evolution of treatment outcomes for resected stage IIIA non-small cell lung cancer over 16 years at a single institution J. Thorac. Cardiovasc. Surg., December 1, 2005; 130(6): 1601 - 1610. [Abstract] [Full Text] [PDF]

				J. L. Port, R. J. Korst, P. C. Lee, M. A. Levin, D. E. Becker, R. Keresztes, and N. K. Altorki Surgical Resection for Residual N2 Disease After Induction Chemotherapy Ann. Thorac. Surg., May 1, 2005; 79(5): 1686 - 1690. [Abstract] [Full Text] [PDF]

				V. Patel and J. B. Shrager Which Patients with Stage III Non-Small Cell Lung Cancer Should Undergo Surgical Resection? Oncologist, May 1, 2005; 10(5): 335 - 344. [Abstract] [Full Text] [PDF]

				M. B. Wallace, J. Ravenel, M. I. Block, M. Fraig, G. Silvestri, S. Wildi, N. Schmulewitz, S. Varadarajulu, S. Roberts, B. J. Hoffman, et al. Endoscopic ultrasound in lung cancer patients with a normal mediastinum on computed tomography Ann. Thorac. Surg., May 1, 2004; 77(5): 1763 - 1768. [Abstract] [Full Text] [PDF]